Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858

Published:2017-01-18 Issue:10 Volume:31 Page:2172-2180
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Eksioglu E A,Chen X,Heider K-H,Rueter B,McGraw K L,Basiorka A A,Wei M,Burnette A,Cheng P,Lancet J,Komrokji R,Djeu J,List A,Wei S

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/leu201721.pdf

Reference39 articles.

1. Nimer SD . Myelodysplastic syndromes. Blood 2008; 111: 4841–4851.

2. Estey E . Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25: 1908–1915.

3. Look AT . Molecular pathogenesis of MDS. Hematology Am Soc Hematol Educ Program 2005, 156–160.

4. Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J et al. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood 2005; 105: 1366–1367.

5. Rothstein G . Disordered hematopoiesis and myelodysplasia in the elderly. J Am Geriatr Soc 2003; 51: S22–S26.

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?;Human Cell;2024-05-30

2. First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome;Clinical and Translational Science;2024-03

3. A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance;Cancer Biology & Therapy;2024-02-02

4. Myelodysplastic Syndrome;Comprehensive Hematology and Stem Cell Research;2024

5. Exploiting innate immunity for cancer immunotherapy;Molecular Cancer;2023-11-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3